These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 16093979

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA.
    J Clin Oncol; 2007 Jul 20; 25(21):3076-81. PubMed ID: 17634486
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.
    Cancer; 2007 Apr 15; 109(8):1689-95. PubMed ID: 17330856
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
    Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, Coltman CA.
    J Urol; 2007 May 15; 177(5):1749-52. PubMed ID: 17437804
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
    Keetch DW, Andriole GL, Ratliff TL, Catalona WJ.
    Urology; 1997 Dec 15; 50(6):901-5. PubMed ID: 9426721
    [Abstract] [Full Text] [Related]

  • 16. [Effect of finasteride on the percentage of free PSA: implications in the early diagnosis of prostatic cancer].
    Morote J, Lorente JA, Raventós CX, López MA, Encabo G, De Torres I, López M, De Torres JA.
    Actas Urol Esp; 1998 Dec 15; 22(10):835-9. PubMed ID: 9949572
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
    Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM.
    J Clin Oncol; 2005 Mar 20; 23(9):1911-20. PubMed ID: 15774783
    [Abstract] [Full Text] [Related]

  • 19. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
    Reed AB, Parekh DJ.
    Curr Opin Urol; 2009 May 20; 19(3):238-42. PubMed ID: 19318950
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.